SXTP
60 DEGREES PHARMACEUTICALS, INC.
Next earnings ≈ Aug 15, 2026 · est. from filing cadence
$1.78
▲ +10.56%$1.78▼ -81.06%
over 1Y
L $1.36EODHDH $10.44
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+10.6%
1W+5.3%
1M+21.9%
3M+17.9%
YTD-13.8%
1Y-81.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Revenue grew 65.5% YoY; but unprofitable (net margin -732.5%).
Revenue (FY2025) $1.01M · FY2025
60 DEGREES PHARMACEUTICALS, INC. shows $1.01M in FY2025 revenue (+65.5% YoY), a -732.5% net margin, and -212.7% ROE.
Supporting the case: revenue grew 65.5% YoY; conservative balance sheet (liabilities/equity 0.57x).
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | $223K | $254K | $608K | $1.01M |
| Gross profit | -$209K | -$221K | $223K | $224K |
| Operating income | -$1.75M | -$5.15M | -$9.72M | -$7.76M |
| Net income | -$6.18M | -$3.77M | -$7.95M | -$7.37M |
| Diluted EPS | -$2.61 | -$59.18 | -$74.17 | -$11.73 |
| Net margin | -2769.5% | -1485.1% | -1308.0% | -732.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$3.38M
EV / EBITDA—
EV / Sales3.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-155.6%
FCF yield-147.6%
Quality & risk
ROIC (est.)-169.5%
Free cash flow-$6.99M
Total debt$153K
Net cash$1.36M
Altman Z-Score-14.97 distress
Piotroski F-Score3/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+79.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-122026-06-15open ↗PRE 14APeriod ending 2026-06-082026-06-08open ↗8-KPeriod ending 2026-06-032026-06-03open ↗3Period ending 2026-05-132026-05-19open ↗8-KPeriod ending 2026-05-132026-05-18open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-15open ↗SCHEDULE 13G/AFiling2026-05-13open ↗10-KPeriod ending 2025-12-312026-03-30open ↗8-KPeriod ending 2026-03-202026-03-20open ↗424B5Filing2026-03-13open ↗
Frequently asked
- Is 60 DEGREES PHARMACEUTICALS, INC. (SXTP) a buy?
- SXTP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 65.5% YoY; but unprofitable (net margin -732.5%).
- What is 60 DEGREES PHARMACEUTICALS, INC.'s quality score?
- SXTP scores 50.852867084393615/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001946563, latest 10-Q filed 2026-05-15) · EODHD · as of 7/1/2026, 11:11:59 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.